Ann Transplant Res | Volume 2, Issue 1 | Research Article | Open Access
Bernadett Borda1*, Attila Nemes2, Csaba Lengyel3, Csilla Keresztes4, Aurél Ottlakán1, Ferenc Rárosi5 and György Lázár1
1Department of Surgery, University of Szeged, Hungary
2Department of Internal Medicine and Cardiology Center, University of Szeged, Hungary
3Department of Internal Medicine, University of Szeged, Hungary
4Department for Medical Translation and Communication, University of Szeged, Hungary
5Department of Medical Physics and Informatics, University of Szeged, Hungary
*Correspondance to: Bernadett Borda
Fulltext PDFBackground: The leading causes of death in patients who died with a functioning allograft are cardiovascular diseases, which account for almost 40 percent of all deaths in this population. Patients and
Methods: We studied prospectively basic data, immunosuppressive therapy, drug levels, serum electrolytes (Na, K, Mg), HbA1C, renal functions (serum creatinine, eGFR, and urea), and urinalysis. Then oral glucose tolerance test was performed as well, and HOMA index was calculated.
Result: The ratio of patients changed at Minute 120 of the test: there were 22 (37%) patients in the normal group, 26 (43% patients in the IFG/IGT group, and 12 (20%) patients in the NODAT group. Regarding basic data, hemodialysis (p=0.662) and body mass index (p=0.854) did not influence the development of diabetes mellitus significantly. Development of NODAT was significantly different between the Tac and CsA groups (p=0.027). Tac increased fasting drug level had a significant effect in the development of NODAT (p=0.036). The results of laboratory tests showed no significant difference in serum electrolytes. HbA1C (p=0.009) and HOMA index (p=0.09) were significantly different. Renal function parameters, such as serum creatinine (p=0.001) and eGFR (p=0.0001), were also significantly different.
Conclusion: In our clinical study, the risk of NODAT related to Tacrolimus is dose dependent and high trough levels enhance this risk, in particular during the new onset diabetes mellitus period.
Kidney transplantation; Calcineurin inhibitors; NODAT; Diabetes mellitus
Borda B, Nemes A, Lengyel C, Keresztes C, Ottlakán A, Rárosi F, et al. The Effects of Calcineurin Inhibitor Levels on New Onset iabetes Mellitus after Kidney Transplantation. Ann Transplant Res. 2018;1(3):1013.